A few months ago, Hims & Hers Health (NYSE: HIMS ) was on life support. Let me take you back to February 2025. Hims was riding high at $70 per share and was a darling of the telehealth sector. ThenI am Sayra Quraishi, a dedicated stock analyst with over a decade of experience. My expertise in market trends and investment strategies in the financial industry. As a part-time investor, I apply my market knowledge to a diverse portfolio, focusing on sectors like technology, healthcare, and renewable energy. I a ...